SCHEMBL10257589

SCHEMBL10257589

CCOC(=O)C1CC1c1c(F)ccc2nn(C)cc12

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
ALDH1A1 P00352 1/20 0.35
ADORA2A P29274 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA1 P30542 1/20 0.34
CXCR2 P25025 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
KDM4E B2RXH2 2/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAP3K5 Q99683 1/20 0.33
SLC6A3 Q01959 2/20 0.33
SLC18A2 Q05940 2/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543633 0.87 MTNR1A (0.39) MTNR1AMTNR1BALDH1A1ADORA2AADORA3
SCHEMBL543148 0.83 MTNR1A (0.40) MTNR1AMTNR1B
SCHEMBL543916 0.80 MAP3K5 (0.38) ALDH1A1ADORA2AADORA3ADORA1CXCR2
SCHEMBL10257416 0.80 MAPT (0.37) MTNR1AMTNR1BALDH1A1ADORA2AADORA3
SCHEMBL2776905 0.76 MTNR1A (0.43) MTNR1AMTNR1BSMN1; SMN2
SCHEMBL2777455 0.76 MTNR1A (0.43) MTNR1AMTNR1BSMN1; SMN2
SCHEMBL2778912 0.76 MTNR1A (0.43) MTNR1AMTNR1BSMN1; SMN2
SCHEMBL543688 0.75 MTNR1A (0.38) MTNR1AMTNR1BHTR2A
SCHEMBL543689 0.75 MTNR1A (0.38) MTNR1AMTNR1BHTR2A
SCHEMBL543998 0.74 MTNR1B (0.52) MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH MTNR1A 1/4885MTNR1B 2/4885ALDH1A1 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.